Med Page Today
JULY 20, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
HCPLive
JULY 20, 2024
One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.
HCPLive
JULY 20, 2024
At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.
HCPLive
JULY 20, 2024
Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.
HCPLive
JULY 20, 2024
Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.
Expert insights. Personalized for you.
137 
Let's personalize your content